Taxotere
Showing 1 - 25 of 895
Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)
Not yet recruiting
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- HB1801
- Taxotere
- (no location specified)
May 8, 2023
Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction Trial in Guangzhou (Docetaxel for injection (Albumin-bound),
Recruiting
- Gastric Adenocarcinoma
- Adenocarcinoma of Gastroesophageal Junction
- Docetaxel for injection (Albumin-bound)
- Taxotere
-
Guangzhou, ChinaEthics Committee of Sun-Yat-Sen University Cancer Center
Jan 27, 2023
Advanced Solid Tumors Trial in Cangzhou (Docetaxel for Injection (Albumin-bound), Taxotere)
Active, not recruiting
- Advanced Solid Tumors
- Docetaxel for Injection (Albumin-bound)
- Taxotere
-
Cangzhou, ChinaCangzhou Central Hospital
Jan 27, 2022
Breast Cancer Trial (Nanoxel M, Taxotere, Doxorubicin)
Not yet recruiting
- Breast Cancer
- Nanoxel M
- +3 more
- (no location specified)
Jan 20, 2022
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial
Recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +3 more
- Cyclophosphamide
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Recurrent NSCLC Trial in Changchun, Shanghai (Cisplatin, Carboplatin, Docetaxel)
Recruiting
- Recurrent Non-small Cell Lung Cancer
- Cisplatin
- +7 more
-
Changchun, Jilin, China
- +2 more
May 3, 2022
Head and Neck Squamous Cell Carcinoma Trial in Norfolk, Omaha (Capecitabine, Docetaxel, Quality-of-Life Assessment)
Terminated
- Head and Neck Squamous Cell Carcinoma
- Capecitabine
- +3 more
-
Norfolk, Nebraska
- +2 more
Aug 10, 2022
Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 12, 2023
Peritoneal Carcinomatosis Trial in Baltimore (Intraperitoneal docetaxel)
Recruiting
- Peritoneal Carcinomatosis
- Intraperitoneal docetaxel
-
Baltimore, MarylandJohns Hopkins University
Nov 7, 2022
Non-muscle-invasive Bladder Cancer Trial (Gemcitabine, Docetaxel, Bacillus Calmette Guerin)
Not yet recruiting
- Non-muscle-invasive Bladder Cancer
- Gemcitabine
- +2 more
- (no location specified)
Sep 9, 2022
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta
Recruiting
- Metastatic Non-Small Lung Cell Cancer
- +4 more
- Docetaxel
- +2 more
-
Atlanta, GeorgiaWinship Cancer Institute of Emory University
Oct 19, 2022
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)
Completed
- Breast Neoplasms
- Epirubicin
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Oct 26, 2022
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Taxotere, Xeloda)
Completed
- Pancreatic Cancer
- Gemcitabine
- +3 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Apr 29, 2021
Head Neck Cancer Trial in Washington (Cisplatinum, Docetaxel, Carboplatin)
Active, not recruiting
- Head and Neck Cancer
- Cisplatinum
- +3 more
-
Washington, District of ColumbiaGeorge Washington University-Medical Faculty Associates
Nov 14, 2022
Soft Tissue Sarcoma Trial in Winston-Salem (drug, radiation, procedure, other)
Recruiting
- Soft Tissue Sarcoma
- Gemcitabine
- +4 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Jan 26, 2023
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,
Not yet recruiting
- Androgen-Independent Prostatic Cancer
- +8 more
- lorigerlimab
- +2 more
- (no location specified)
May 4, 2023
NSCLC Trial (Pembrolizumab, Docetaxel)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- Docetaxel
- (no location specified)
Aug 18, 2022
HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)
Recruiting
- HER-2 Positive Breast Cancer
- TCbHP VS ddEC-THP
-
Tianjin, Tianjin, ChinaBreast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial
Not yet recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +4 more
- Biospecimen Collection
- +9 more
- (no location specified)
Jun 26, 2023